Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-ranging randomized open-label trial of favipiravir tablets in ordinary COVID-19 pneumonia
ChiCTR2000029996Phase 2Recruiting
- Sponsor
- Beijing Chaoyang Hospital, Capital Medical University
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of favipiravir in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Beijing Chaoyang Hospital, Capital Medical University. Primary endpoint: Time to clinical recovery. Started Feb 2020; status: recruiting.
02
Drugs
favipiravir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2000029996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000029996.